Takeda Pharmaceutical (NYSE:TAK - Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 3.330-3.330 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.
Takeda Pharmaceutical Stock Down 0.9 %
TAK traded down $0.12 during mid-day trading on Monday, reaching $13.28. 1,241,494 shares of the stock were exchanged, compared to its average volume of 2,062,472. Takeda Pharmaceutical has a 1 year low of $12.57 and a 1 year high of $15.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market capitalization of $42.24 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. The company has a 50 day moving average price of $13.31 and a two-hundred day moving average price of $13.89.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts anticipate that Takeda Pharmaceutical will post 1.64 EPS for the current year.
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
